Literature DB >> 2070555

Examination of serum class I antigen in liver-transplanted rats.

R Sumimoto1, T Shinomiya.   

Abstract

We examined the appearance of donor (DA) type class I antigen in the serum of rats that had received isogeneic (DA----DA) or allogeneic (DA----PVG, DA----BN, DA----LEW) liver transplants with or without cyclosporin A treatment, using two-site enzyme immunoassay. We also tested the serum titre of class I antigen in the normal DA rats with either 70% hepatectomy or cyclosporin A treatment, in order to clarify the relationship between the fluctuation in the serum titre of class I antigen in the recipient and the outcome of the transplanted liver graft. The suppression of liver graft rejection by cyclosporin A treatment significantly lowered the serum level of donor liver-derived class I antigen as compared with that of the recipient without cyclosporin A for a certain period. However, there was almost no correlation between the intensity of rejection of the liver graft and the serum level type class I among these allogeneic rejection and non-rejection liver transplantation combinations. The amount of donor-type class I antigen in the recipient's serum is dependent on whether the grafted liver is severely damaged following partial hepatectomy, whether the liver has associated biliary complications or ischaemic damage, or whether the liver has had absolute residual parenchymal cell volume or function following liver rejection. Our results suggest that the appearance of donor type class I antigen following liver transplantation is dependent on many factors, and therefore the titre of serum class 1 antigen may not always be a decisive indicator of liver graft rejection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070555      PMCID: PMC1535728          DOI: 10.1111/j.1365-2249.1991.tb05691.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody.

Authors:  R Sumimoto; N Kamada
Journal:  Transplantation       Date:  1990-10       Impact factor: 4.939

2.  Techniques for orthotopic liver transplantation in the rat and some studies of the immunologic responses to fully allogeneic liver grafts.

Authors:  F A Zimmermann; G W Butcher; H S Davies; G Brons; N Kamada; O Türel
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Anti HL-A2 inhibitor in normal human serum.

Authors:  J J van Rood; A van Leeuwen; M C van Santen
Journal:  Nature       Date:  1970-04-25       Impact factor: 49.962

4.  Isolation of six monoclonal alloantibodies against rat histocompatibility antigens: clonal competition.

Authors:  J C Howard; G W Butcher; D R Licence; G Galfrè; B Wright; C Milstein
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

5.  Characterization of molecules bearing HLA determinants in serum and urine.

Authors:  C Vincent; J P Revillard
Journal:  Transplant Proc       Date:  1979-06       Impact factor: 1.066

6.  Secretion of a transplantation-related antigen.

Authors:  M Kress; D Cosman; G Khoury; G Jay
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

7.  Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens.

Authors:  N Kamada; G Brons; H S Davies
Journal:  Transplantation       Date:  1980-05       Impact factor: 4.939

8.  Expression of the major histocompatibility complex antigens on different liver cellular components in rat and man.

Authors:  I Lautenschlager; P Häyry
Journal:  Scand J Immunol       Date:  1981-10       Impact factor: 3.487

9.  A surgical experience with five hundred thirty liver transplants in the rat.

Authors:  N Kamada; R Y Calne
Journal:  Surgery       Date:  1983-01       Impact factor: 3.982

10.  Antigen-specific immunosuppression induced by liver transplantation in the rat.

Authors:  N Kamada; D G Wight
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.